The Phase 2 weight-loss results were genuinely strong, which is why this compound still circulates years after its development stalled. The TIPO-1 trial, published by Astrup and colleagues in The Lancet in 2008, showed substantial dose-dependent weight loss. It also showed dose-dependent increases in heart rate, up to roughly seven to eight beats per minute, and elevated blood pressure at higher doses. Sympathomimetic and psychiatric adverse events were flagged as class concerns in subsequent analysis. The clearest signal about how seriously the cardiovascular effect was taken is that the follow-on development programme paired it with a beta-blocker. That is not a routine formulation choice. It is an attempt to manage a known problem. Worth noting for classification purposes: this is a triple monoamine reuptake inhibitor, a stimulant-class drug, not a peptide at all, despite where it usually gets filed.